Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Notes Payables (2022 - 2025)

Historic Notes Payables for Dexcom (DXCM) over the last 4 years, with Q3 2025 value amounting to $1.2 billion.

  • Dexcom's Notes Payables changed N/A to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year change of. This contributed to the annual value of $1.2 billion for FY2024, which is N/A changed from last year.
  • Latest data reveals that Dexcom reported Notes Payables of $1.2 billion as of Q3 2025.
  • Over the past 5 years, Dexcom's Notes Payables peaked at $1.2 billion during Q3 2025, and registered a low of $124.2 million during Q3 2023.
  • Over the past 4 years, Dexcom's median Notes Payables value was $989.1 million (recorded in 2023), while the average stood at $908.3 million.